Oramed To Receive $50M Investment From Chinese Firms

July 8, 2015 | Oramed Pharmaceuticals announced that it signed a non-binding letter of intent for a $50 million investment from two leading Chinese firms. The first is Sinopharm Capital Management, a top Chinese pharmaceutical investment company, and the second is Hefei Life Science & Technology Park Investments and Development Co., a Chinese firm that invests in early-stage companies and owns an insulin manufacturing plant. Oramed recently announced that it would begin advanced trials on its orally administered insulin pill. As part of their investment, the investors will receive a 10 percent stake in the company as well as the exclusive licence to market Oramed’s products in China. Oramed was founded in 2006 and is headquartered in Jerusalem.